The Future of Seizure Rescue Therapy
Epilepsy affects at least three million people in the United States. A third of these people suffer from refractory epilepsy with uncontrolled seizures, which cannot be helped by currently available antiepileptic drugs. Engage Therapeutics is developing Staccato Alprazolam with the goal of terminating an active prolonged focal, generalized or cluster seizure episode in patients who experience breakthrough seizures even while on an antiepileptic drug.
Staccato Alprazolam has the potential to be the “first-in class” REST (Rapid Epileptic Seizure Termination) therapy, providing a rescue option beyond the currently available treatments for acute repetitive seizures (ARS). It is estimated that Staccato Alprazolam could benefit 1.2 million people in the U.S. who experience prolonged focal or generalized seizures versus the significantly smaller population of people (180,000) who experience ARS.
Technology that can predict oncoming seizures continues to advance. Coupling this technology with a treatment that can stop an active seizure could enable us to limit the physical, psychological, and financial burden that seizures cause. This technology may expand the number of patients that could potentially benefit from Staccato Alprazolam.